GRAIL, Inc. has established a substantial clinical evidence base for its Galleri multi-cancer early detection (MCED) blood test through large-scale studies such as PATHFINDER 2 and the NHS-Galleri Trial. The company submitted its PMA application to the FDA in early 2026, marking a critical regulatory inflection point that could drive broader market adoption. While operational losses narrowed substantially in 2025, driven by scaling efficiencies, reimbursement uncertainty and regulatory risks remain significant challenges. GRAIL’s capital position is solid with strong liquidity supported by equity infusions from Samsung, though it has yet to generate positive cash flows or returns.